MetaCap

iSpecimen (ISPC) vs MaxCyte (MXCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MaxCyte is the larger company by market cap ($141.5 million vs $2.6 million), about 53.5 times the size. MaxCyte converts more of its revenue into profit, with a net margin of -135.1% versus -543.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ISPC-58.52%MXCT+31.73%
+73%+4%-65%
Oct 7, 20261 yearNov 20, 2026
ISPC-59.62%MXCT+35.64%
+63%-1%-65%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ISPC versus MXCT key metrics
MetricISPCMXCT
Share price$0.4563$1.37
Market cap$2.64M$141.45M
1-day change-13.58%+7.03%
YTD return—-11.61%
1-year return—-17.96%
5-year return—-85.92%
EPS (TTM)$-52.98$-0.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.93M$33.03M
Revenue growth (YoY)-79.24%-14.50%
Net income (latest FY)$-10.49M$-44.63M
Gross margin11.18%81.16%
Operating margin-465.42%-157.14%
Net margin-543.68%-135.14%
52-week high$27.44$1.80
52-week low$0.432$0.643
Distance from 52-week high-98.34%-23.89%
Analyst consensus—strong_buy
Avg. price target upside—+200.00%
Average volume598.66K1.04M
Shares outstanding5.79M103.25M
Employees791
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MaxCyte is about 53.5 times larger than iSpecimen by market value ($141.45M vs $2.64M).
  • MaxCyte is more profitable, keeping -135.1 cents of every revenue dollar as net income versus -543.7 cents for iSpecimen.
  • MaxCyte grew revenue faster in its latest fiscal year (-14.50% vs -79.24%).

About iSpecimen

ISPC stock →

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees

About MaxCyte

MXCT stock →

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees

ISPC vs MXCT FAQ

Which is bigger, iSpecimen or MaxCyte?

MaxCyte (MXCT) is larger, with a market capitalization of $141.45M compared with $2.64M for iSpecimen (ISPC).

Are iSpecimen and MaxCyte in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons